Back to today’s briefing

Story perspectives

Sarepta Stock Rises 6.8% Amid Job Cuts, FDA Update

10/3/2025

50 4

Summary

Story summary

Sarepta Therapeutics' stock closed at $19.57 on October 2, 2025, up 6.8%, but remains down 82% year-to-date.
In July 2025, Sarepta Therapeutics cut 500 jobs and shifted to RNAi therapies, partnering with Arrowhead Pharmaceuticals.
The U.S. Food and Drug Administration (FDA) lifted Elevidys' ambulatory pause after safety reviews; non-ambulatory holds remain, while analysts show mixed ratings and a Hold consensus.

1 of 1

Story summary

Sarepta Therapeutics' stock closed at $19.57 on October 2, 2025, up 6.8%, but remains down 82% year-to-date.
In July 2025, Sarepta Therapeutics cut 500 jobs and shifted to RNAi therapies, partnering with Arrowhead Pharmaceuticals.
The U.S. Food and Drug Administration (FDA) lifted Elevidys' ambulatory pause after safety reviews; non-ambulatory holds remain, while analysts show mixed ratings and a Hold consensus.